Drug Trial Radar · NCT03684811
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Last checked: Nov 20, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
93
Actual
Start
Nov 1, 2018
Primary completion
May 24, 2021
Study completion Jun 13, 2022
Sponsor
- Lead sponsor
- Forma Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 26, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored. Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102 + nivolumab (hepatobiliary tumors), and FT-2102 + gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.
Conditions
- Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
- Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
- Cohort 3a and 3b: Chondrosarcoma
- Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
- Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations
Interventions
FT-2102Drug
FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.
AzacitidineDrug
Azacitidine will be administered per the site's standard of care.
NivolumabBiological
Nivolumab will be administered per the site's standard of care.
Gemcitabine and CisplatinDrug
Gemcitabine and cisplatin will be administered per the site's standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Dose Limiting Toxicity (DLT)Time frame: Day 1-28
- Overall Response Rate (ORR)Time frame: While on treatment
Locations
26 sites in 6 countries. Site status is shown where the registry gives one.
Banner MD Anderson
Gilbert, Arizona
University of Colorado Anschutz Medical Campus
Aurora, Colorado
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida
Northwestern University, Lurie Comprehensive Cancer Center
Chicago, Illinois
University of Iowa, Holden Comprehensive Cancer Institute
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Columbia University Medical Center
New York, New York
Baylor Scott and White Medical Center
Temple, Texas
University of Utah, Huntsman Cancer Hospital
Salt Lake City, Utah
Medical College of Wisconsin, Froedtert Hospital
Milwaukee, Wisconsin
Peter MacCallum Cancer Centre
Melbourne, Australia
Austin Hospital
Heidelberg, Victoria, Australia
Centre de Lutte Contre Cancer (CLCC) - Institute Bergonie
Bordeaux, France
Centre de Lutte Cancre (CLCC) - Lyon
Lyon, France
Hospital de la Timone
Marseille, France
Institut Gustave Roussy Cancer Campus
Villejuif, France
Seoul National University Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Vall D'Hebron University Hospital
Barcelona, Spain
Cancer Research Beatson Institute
Glasgow, United Kingdom
The Royal Marsden Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.